ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulato…

Biotechnology

US, San Diego [HQ]

FA

Fundamental Analysis · Most Recent Quarter

A dedicated fundamental analysis might help you to get a quick overview
of the financial stability. It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale

Framework:

Valuation n.A. n.A.

Profitability n.A. n.A.

Fin. Growth n.A. n.A.

Leverage & Liquidity n.A. n.A.

Per Share Metrics n.A. n.A.

Fin. Health n.A. n.A.

1 Financial Health

Metric	Q₃	Q₄	Δ in %
Current Ratio	n.A.	n.A.	n.A.
Debt/Assets	n.A.	n.A.	n.A.
Debt/Equity	n.A.	n.A.	n.A.
Net Debt/EBITDA	n.A.	n.A.	n.A.
Naive Interpretation	member

2 Per Share

Metric	Q₃	Q₄	Δ in %
Book Value	n.A.	n.A.	n.A.
Cash	n.A.	n.A.	n.A.
Capex	n.A.	n.A.	n.A.
Free Cash Flow	n.A.	n.A.	n.A.
Revenue	n.A.	n.A.	n.A.
Naive Interpretation	member

3 Profitability

Metric	Q₃	Q₄	Δ in %
Gross Margin	n.A.	n.A.	n.A.
Operating Margin	n.A.	n.A.	n.A.
ROA	n.A.	n.A.	n.A.
ROE	n.A.	n.A.	n.A.
ROIC	n.A.	n.A.	n.A.
Naive Interpretation	member

4 Valuation

The "Valuation Entry" for the Focus of IBRX is permitted for members.

5 Growth

The "Growth Entry" for the Focus of IBRX is permitted for members.

6 Leverage & Liquidity

FA

The "Valuation Entry" for the Focus of IBRX is permitted for members.

The "Growth Entry" for the Focus of IBRX is permitted for members.

The "Leverage & Liquidity Entry" for the Focus of IBRX is permitted for members.